Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I

One gene can be knockout of the T cells to produce a T-like NK cells which obtain killing function of both T effector cells and NK cells. We will collect appropriate patient's T cells, produce T-like NK cells (ITNK), and infuse the ITNK/CAR-ITNK cells back to the patients to treat various of cancers.

Inclusion criteria

• Patients with advanced cancer, which express low or no MHC-I.
• Life expectancy >12 weeks
• Adequate heart,lung,liver,kidney function
• Available autologous T cells
• Informed consent explained to, understood by and signed by patient/guardian. 6. Patient/guardian given copy of informed consent.

Exclusion criteria

• Had accepted gene therapy before;
• Severe virus infection such as HBV,HCV,HIV,et al
• Known HIV positivity
• History of liver or other organ transplantation
• Active infectious disease related to bacteria, virus,fungi,et al
• Other severe diseases that the investigators consider not appropriate;
• Pregnant or lactating women
• Systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent/kg/day)
• Other conditions that the investigators consider not appropriate.